Increased Sphingosine-1-Phosphate Serum Concentrations in Subjects with Periodontitis: A Matter of Inflammation

References

• Kumar V, Abbas AK, Aster JC. Robbins & Cotran Pathologic Basis of Disease. 10th ed. International edition; 2021
   Google Scholar
• Kassebaum NJ, Bernabé E, Dahiya M, Bhandari B, Murray CJL, Marcenes W. Global burden of severe periodontitis in 1990–2010: a systematic review and meta-regression. J Dent Res. 2014;93(11):1045–1053. doi:10.1177/0022034514552491
   PubMed Web of Science ®Google Scholar
• Hoffmann T. Krankheits- und Versorgungsprävalenzen bei Jüngeren Erwachsenen (35-bis 44-Jährige). In: Jordan AR, Micheelis W, editors. Fünfte Deutsche Mundgesundheitsstudie (DMS V). Köln: Deutscher Ärzteverlag (DÄV); 2016:312–334.
   Google Scholar
• Kocher THB. Krankheits- und Versorgungsprävalenzen bei Jüngeren Senioren (65-bis 74-Jährige). In: Jordan AR, Micheelis W, editors. Fünfte Deutsche Mundgesundheitsstudie (DMS V). Köln: Deutscher Ärzteverlag (DÄV); 2016:396–415.
   Google Scholar
• Kocher T, Holtfreter B. Editorial: Is the prevalence of periodontitis declining or not? Oral Health Prev Dent. 2017;15(6):501–502.
   PubMed Web of Science ®Google Scholar
• Schützhold S, Kocher T, Biffar R, et al. Changes in prevalence of periodontitis in two German population-based studies. J Clin Periodontol. 2015;42(2):121–130. doi:10.1111/jcpe.12352
   PubMed Web of Science ®Google Scholar
• Hajishengallis G. Periodontitis: from microbial immune subversion to systemic inflammation. Nat Rev Immunol. 2015;15(1):30–44. doi:10.1038/nri3785
   PubMed Web of Science ®Google Scholar
• Schenkein HA, Loos BG. Inflammatory mechanisms linking periodontal diseases to cardiovascular diseases. J Clin Periodontol. 2013;40(Suppl 14):S51–69. doi:10.1111/jcpe.12060
   PubMedGoogle Scholar
• Chistiakov DA, Orekhov AN, Bobryshev YV. Links between atherosclerotic and periodontal disease. Exp Mol Pathol. 2016;100(1):220–235.
   PubMed Web of Science ®Google Scholar
• Holtfreter B, Empen K, Gläser S, et al. Periodontitis is associated with endothelial dysfunction in a general population: a cross-sectional study. PLoS One. 2013;8(12):e84603. doi:10.1371/journal.pone.0084603
   PubMed Web of Science ®Google Scholar
• Yu Y-H, Chasman DI, Buring JE, Rose L, Ridker PM. Cardiovascular risks associated with incident and prevalent periodontal disease. J Clin Periodontol. 2015;42(1):21–28. doi:10.1111/jcpe.12335
   PubMed Web of Science ®Google Scholar
• Carrizales-Sepúlveda EF, Ordaz-Farías A, Vera-Pineda R, Flores-Ramírez R. Periodontal disease, systemic inflammation and the risk of cardiovascular disease. Heart Lung Circ. 2018;27(11):1327–1334. doi:10.1016/j.hlc.2018.05.102
   PubMed Web of Science ®Google Scholar
• Tomás I, Diz P, Tobías A, Scully C, Donos N. Periodontal health status and bacteraemia from daily oral activities: systematic review/meta-analysis. J Clin Periodontol. 2012;39(3):213–228. doi:10.1111/j.1600-051X.2011.01784.x
   PubMed Web of Science ®Google Scholar
• Obinata H, Hla T. Sphingosine 1-phosphate and inflammation. Int Immunol. 2019;31(9):617–625. doi:10.1093/intimm/dxz037
   PubMed Web of Science ®Google Scholar
• Stepanovska B, Huwiler A. Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases. Pharmaco Res. 2020;154:104170. doi:10.1016/j.phrs.2019.02.009
   PubMed Web of Science ®Google Scholar
• Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol. 2003;4(5):397–407. doi:10.1038/nrm1103
   PubMed Web of Science ®Google Scholar
• Blaho VA, Hla T. An update on the biology of sphingosine 1-phosphate receptors. J Lipid Res. 2014;55(8):1596–1608. doi:10.1194/jlr.R046300
   PubMed Web of Science ®Google Scholar
• Rosen H, Stevens RC, Hanson M, Roberts E, Oldstone MBA. Sphingosine-1-phosphate and its receptors: structure, signaling, and influence. Annu Rev Biochem. 2013;82(1):637–662. doi:10.1146/annurev-biochem-062411-130916
   PubMedGoogle Scholar
• Bode C, Sensken S-C, Peest U, et al. Erythrocytes serve as a reservoir for cellular and extracellular sphingosine 1-phosphate. J Cell Biochem. 2010;109(6):1232–1243. doi:10.1002/jcb.22507
   PubMed Web of Science ®Google Scholar
• Olivera A, Allende ML, Proia RL. Shaping the landscape: metabolic regulation of S1P gradients. Biochim Biophys Acta. 2013;1831(1):193–202. doi:10.1016/j.bbalip.2012.06.007
   PubMed Web of Science ®Google Scholar
• Ulrych T, Böhm A, Polzin A, et al. Release of sphingosine-1-phosphate from human platelets is dependent on thromboxane formation. J Thromb Haemost. 2011;9(4):790–798. doi:10.1111/j.1538-7836.2011.04194.x
   PubMed Web of Science ®Google Scholar
• Soltau I, Mudersbach E, Geissen M, et al. Serum-sphingosine-1-phosphate concentrations are inversely associated with atherosclerotic diseases in humans. PLoS One. 2016;11(12):e0168302. doi:10.1371/journal.pone.0168302
   PubMed Web of Science ®Google Scholar
• Winkler MS, Nierhaus A, Holzmann M, et al. Decreased serum concentrations of sphingosine-1-phosphate in sepsis. Critical Care. 2015;19(1):372. doi:10.1186/s13054-015-1089-0
   PubMedGoogle Scholar
• Moritz E, Wegner D, Groß S, et al. Reference intervals for serum sphingosine-1-phosphate in the population-based study of health in Pomerania. Clin Chim Acta. 2017;468:25–31. doi:10.1016/j.cca.2017.01.029
   PubMed Web of Science ®Google Scholar
• Moritz E, Wegner D, Groß S, et al. Data on subgroup specific baseline characteristics and serum sphingosine-1-phosphate concentrations in the Study of Health in Pomerania. Data Brief. 2017;12:46–50. doi:10.1016/j.dib.2017.03.019
   PubMedGoogle Scholar
• Ishii M, Kikuta J. Sphingosine-1-phosphate signaling controlling osteoclasts and bone homeostasis. Biochim Biophys Acta. 2013;1831(1):223–227. doi:10.1016/j.bbalip.2012.06.002
   PubMed Web of Science ®Google Scholar
• Weske S, Vaidya M, Reese A, et al. Targeting sphingosine-1-phosphate lyase as an anabolic therapy for bone loss. Nat Med. 2018;24(5):667–678. doi:10.1038/s41591-018-0005-y
   PubMed Web of Science ®Google Scholar
• Völzke H, Alte D, Schmidt CO, et al. Cohort profile: the study of health in Pomerania. Int J Epidemiol. 2011;40(2):294–307. doi:10.1093/ije/dyp394
   PubMed Web of Science ®Google Scholar
• Völzke H, Ittermann T, Schmidt CO, et al. Prevalence trends in lifestyle-related risk factors. Dtsch Arztebl Int. 2015;112(11):185–192. doi:10.3238/arztebl.2015.0185
   PubMed Web of Science ®Google Scholar
• Poul Erik Petersen, Ramon J Baez, World Health Organization. Citation: Petersen PE, Ramon RJ & World Health Organization. Oral health surveys: basic methods, 5th ed. Geneva:World Health Organisation;2013
   Google Scholar
• Demmer RT, Kocher T, Schwahn C, Völzke H, Jacobs Jr DR, Desvarieux M. Refining exposure definitions for studies of periodontal disease and systemic disease associations. Community Dent Oral Epidemiol. 2008;36(6):493–502. doi:10.1111/j.1600-0528.2008.00435.x
   PubMed Web of Science ®Google Scholar
• Holtfreter B, Albandar JM, Dietrich T, et al. Standards for reporting chronic periodontitis prevalence and severity in epidemiologic studies: proposed standards from the Joint EU/USA periodontal epidemiology working group. J Clin Periodontol. 2015;42(5):407–412. doi:10.1111/jcpe.12392
   PubMed Web of Science ®Google Scholar
• Page RC, Eke PI. Case definitions for use in population-based surveillance of periodontitis. J Periodontol. 2007;78(7 Suppl):1387–1399. doi:10.1902/jop.2007.060264
   Web of Science ®Google Scholar
• Meisel P, Giebel J, Peters M, et al. Expression of N-acetyltransferases in periodontal granulation tissue. J Dent Res. 2002;81(5):349–353. doi:10.1177/154405910208100512
   PubMed Web of Science ®Google Scholar
• Meisel P, Pink C, Pitchika V, Nauck M, Völzke H, Kocher T. Competing interplay between systemic and periodontal inflammation: obesity overrides the impact of oral periphery. Clin Oral Investig. 2020.
   Web of Science ®Google Scholar
• Pink C, Kocher T, Meisel P, et al. Longitudinal effects of systemic inflammation markers on periodontitis. J Clin Periodontol. 2015;42(11):988–997. doi:10.1111/jcpe.12473
   PubMed Web of Science ®Google Scholar
• Gocke C, Holtfreter B, Meisel P, et al. Abdominal obesity modifies long-term associations between periodontitis and markers of systemic inflammation. Atherosclerosis. 2014;235(2):351–357. doi:10.1016/j.atherosclerosis.2014.05.926
   PubMed Web of Science ®Google Scholar
• Allende ML, Bektas M, Lee BG, et al. Sphingosine-1-phosphate lyase deficiency produces a pro-inflammatory response while impairing neutrophil trafficking. J Biol Chem. 2011;286(9):7348–7358. doi:10.1074/jbc.M110.171819
   PubMed Web of Science ®Google Scholar
• Ledgerwood LG, Lal G, Zhang N, et al. The sphingosine 1-phosphate receptor 1 causes tissue retention by inhibiting the entry of peripheral tissue T lymphocytes into afferent lymphatics. Nat Immunol. 2008;9(1):42–53. doi:10.1038/ni1534
   PubMed Web of Science ®Google Scholar
• Xiao L, Zhou Y, Friis T, Beagley K, Xiao Y. S1P-S1PR1 signaling: the “Sphinx” in osteoimmunology. Front Immunol. 2019;10:1409. doi:10.3389/fimmu.2019.01409
   PubMed Web of Science ®Google Scholar
• Mahajan-Thakur S, Böhm A, Jedlitschky G, Schrör K, Rauch BH. Sphingosine-1-phosphate and its receptors: a mutual link between blood coagulation and inflammation. Mediators Inflamm. 2015;2015:831059. doi:10.1155/2015/831059
   PubMed Web of Science ®Google Scholar
• Kim E-S, Cha Y, Ham M, et al. Inflammatory lipid sphingosine-1-phosphate upregulates C-reactive protein via C/EBPβ and potentiates breast cancer progression. Oncogene. 2014;33(27):3583–3593. doi:10.1038/onc.2013.319
   PubMed Web of Science ®Google Scholar
• Bougault C, El Jamal A, Briolay A, et al. Involvement of sphingosine kinase/sphingosine 1-phosphate metabolic pathway in spondyloarthritis. Bone. 2017;103:150–158. doi:10.1016/j.bone.2017.07.002
   PubMed Web of Science ®Google Scholar
• Choi HS, Kim KH, Jin S, et al. Decreased expression of sphingosine-1-phosphate receptor 1 in the blood leukocyte of rheumatoid arthritis patients. Immune Netw. 2018;18(5):e39. doi:10.4110/in.2018.18.e39
   PubMed Web of Science ®Google Scholar
• Böhm A, Flößer A, Ermler S, et al. Factor-Xa-induced mitogenesis and migration require sphingosine kinase activity and S1P formation in human vascular smooth muscle cells. Cardiovasc Res. 2013;99(3):505–513. doi:10.1093/cvr/cvt112
   PubMed Web of Science ®Google Scholar
• Halin C, Scimone ML, Bonasio R, et al. The S1P-analog FTY720 differentially modulates T-cell homing via HEV: t-cell-expressed S1P1 amplifies integrin activation in peripheral lymph nodes but not in Peyer patches. Blood. 2005;106(4):1314–1322. doi:10.1182/blood-2004-09-3687
   PubMed Web of Science ®Google Scholar
• Maceyka M, Spiegel S. Sphingolipid metabolites in inflammatory disease. Nature. 2014;510(7503):58–67. doi:10.1038/nature13475
   PubMed Web of Science ®Google Scholar
• Schwab SR, Cyster JG. Finding a way out: lymphocyte egress from lymphoid organs. Nat Immunol. 2007;8(12):1295–1301. doi:10.1038/ni1545
   PubMed Web of Science ®Google Scholar
• Kułakowska A, Zendzian-Piotrowska M, Baranowski M, et al. Intrathecal increase of sphingosine 1-phosphate at early stage multiple sclerosis. Neurosci Lett. 2010;477(3):149–152. doi:10.1016/j.neulet.2010.04.052
   PubMed Web of Science ®Google Scholar
• Snider AJ, Kawamori T, Bradshaw SG, et al. A role for sphingosine kinase 1 in dextran sulfate sodium-induced colitis. FASEB J. 2009;23(1):143–152. doi:10.1096/fj.08-118109
   PubMed Web of Science ®Google Scholar
• Liang J, Nagahashi M, Kim EY, et al. Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell. 2013;23(1):107–120. doi:10.1016/j.ccr.2012.11.013
   PubMed Web of Science ®Google Scholar
• Suh JH, Saba JD. Sphingosine-1-phosphate in inflammatory bowel disease and colitis-associated colon cancer: the fat’s in the fire. Transl Cancer Res. 2015;4(5):469–483. doi:10.3978/j.issn.2218-676X.2015.10.06
   PubMed Web of Science ®Google Scholar
• Lai W-Q, Irwan AW, Goh HH, et al. Anti-inflammatory effects of sphingosine kinase modulation in inflammatory arthritis. J Immunol. 2008;181(11):8010–8017. doi:10.4049/jimmunol.181.11.8010
   PubMed Web of Science ®Google Scholar
• Kitano M, Hla T, Sekiguchi M, et al. Sphingosine 1-phosphate/sphingosine 1-phosphate receptor 1 signaling in rheumatoid synovium: regulation of synovial proliferation and inflammatory gene expression. Arthritis Rheum. 2006;54(3):742–753. doi:10.1002/art.21668
   PubMedGoogle Scholar
• Eskan MA, Rose BG, Benakanakere MR, Lee M-J, Kinane DF. Sphingosine 1-phosphate 1 and TLR4 mediate IFN-beta expression in human gingival epithelial cells. J Immunol. 2008;180(3):1818–1825. doi:10.4049/jimmunol.180.3.1818
   PubMed Web of Science ®Google Scholar
• Eskan MA, Rose BG, Benakanakere MR, et al. TLR4 and S1P receptors cooperate to enhance inflammatory cytokine production in human gingival epithelial cells. Eur J Immunol. 2008;38(4):1138–1147. doi:10.1002/eji.200737898
   PubMed Web of Science ®Google Scholar
• Yu H, Sun C, Argraves KM. Periodontal inflammation and alveolar bone loss induced by Aggregatibacter actinomycetemcomitans is attenuated in sphingosine kinase 1-deficient mice. J Periodontal Res. 2016;51(1):38–49. doi:10.1111/jre.12276
   PubMed Web of Science ®Google Scholar
• Yu H, Herbert BA, Valerio M, Yarborough L, Hsu L-C, Argraves KM. FTY720 inhibited proinflammatory cytokine release and osteoclastogenesis induced by Aggregatibacter actinomycetemcomitans. Lipids Health Dis. 2015;14(1):66. doi:10.1186/s12944-015-0057-7
   PubMedGoogle Scholar
• Lee D-E, Kim J-H, Choi S-H, Cha J-H, Bak E-J, Yoo Y-J. The sphingosine-1-phosphate receptor 1 binding molecule FTY720 inhibits osteoclast formation in rats with ligature-induced periodontitis. J Periodontal Res. 2017;52(1):33–41. doi:10.1111/jre.12366
   PubMed Web of Science ®Google Scholar
• Lucaciu A, Brunkhorst R, Pfeilschifter JM, Pfeilschifter W, Subburayalu J. The S1P-S1PR Axis in neurological disorders-insights into current and future therapeutic perspectives. Cells. 2020;9(6):1515. doi:10.3390/cells9061515
   PubMed Web of Science ®Google Scholar
• Han M, Sun T, Chen H, Han M, Wang D. Potential sphingosine-1-phosphate-related therapeutic targets in the treatment of cerebral ischemia reperfusion injury. Life Sci. 2020;249:117542. doi:10.1016/j.lfs.2020.117542
   PubMed Web of Science ®Google Scholar
• Zhang L, Dong Y, Wang Y, Hu W, Dong S, Chen Y. Sphingosine-1-phosphate (S1P) receptors: promising drug targets for treating bone-related diseases. J Cell Mol Med. 2020;24(8):4389–4401. doi:10.1111/jcmm.15155
   PubMed Web of Science ®Google Scholar
• Ardawi M-SM, Rouzi AA, Al-Senani NS, Qari MH, Elsamanoudy AZ, Mousa SA. High plasma sphingosine 1-phosphate levels predict osteoporotic fractures in postmenopausal women: the center of excellence for osteoporosis research Study.. J Bone Metab. 2018;25(2):87–98. doi:10.11005/jbm.2018.25.2.87
   PubMedGoogle Scholar
• Pchejetski D, Bohler T, Brizuela L, et al. FTY720 (fingolimod) sensitizes prostate cancer cells to radiotherapy by inhibition of sphingosine kinase-1. Cancer Res. 2010;70(21):8651–8661. doi:10.1158/0008-5472.CAN-10-1388
   PubMed Web of Science ®Google Scholar
• Tonelli F, Lim KG, Loveridge C, et al. FTY720 and (S)-FTY720 vinylphosphonate inhibit sphingosine kinase 1 and promote its proteasomal degradation in human pulmonary artery smooth muscle, breast cancer and androgen-independent prostate cancer cells. Cell Signal. 2010;22(10):1536–1542. doi:10.1016/j.cellsig.2010.05.022
   PubMed Web of Science ®Google Scholar
• Vessey DA, Kelley M, Zhang J, Li L, Tao R, Karliner JS. Dimethylsphingosine and FTY720 inhibit the SK1 form but activate the SK2 form of sphingosine kinase from rat heart. J Biochem Mol Toxicol. 2007;21(5):273–279. doi:10.1002/jbt.20193
   PubMed Web of Science ®Google Scholar